IONSĀ – Ionis Pharmaceuticals, Inc.
Float Short %
9.8
Margin Of Safety %
Put/Call OI Ratio
0.99
EPS Next Q Diff
0.21
EPS Last/This Y
1.39
EPS This/Next Y
-0.63
Price
83.17
Target Price
93.58
Analyst Recom
1.67
Performance Q
11.61
Upside
-126.7%
Beta
0.31
Ticker: IONS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | IONS | 80.3 | 0.78 | 0.80 | 21450 |
| 2026-01-26 | IONS | 81 | 0.78 | 0.09 | 21438 |
| 2026-01-27 | IONS | 82.21 | 0.78 | 2.19 | 21478 |
| 2026-01-28 | IONS | 81.92 | 0.80 | 2.35 | 21909 |
| 2026-01-29 | IONS | 83.83 | 0.96 | 0.10 | 26117 |
| 2026-01-30 | IONS | 82.66 | 0.96 | 0.08 | 26156 |
| 2026-02-02 | IONS | 82.71 | 0.96 | 8.39 | 26178 |
| 2026-02-03 | IONS | 84.83 | 0.99 | 0.72 | 26671 |
| 2026-02-05 | IONS | 83.5 | 0.97 | 0.29 | 27023 |
| 2026-02-09 | IONS | 84.8 | 0.94 | 0.18 | 31680 |
| 2026-02-10 | IONS | 84.27 | 0.94 | 0.20 | 31699 |
| 2026-02-11 | IONS | 84.35 | 0.94 | 29.59 | 31697 |
| 2026-02-12 | IONS | 81.79 | 0.98 | 0.43 | 32410 |
| 2026-02-13 | IONS | 80.63 | 0.98 | 0.17 | 32463 |
| 2026-02-17 | IONS | 81.35 | 0.98 | 1.05 | 32464 |
| 2026-02-18 | IONS | 82.18 | 0.97 | 1.06 | 32349 |
| 2026-02-19 | IONS | 82.91 | 0.97 | 2.84 | 32393 |
| 2026-02-20 | IONS | 83.14 | 0.99 | 0.42 | 32667 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | IONS | 80.25 | -189.3 | -203.5 | -1.65 |
| 2026-01-26 | IONS | 81.01 | -189.3 | -214.9 | -1.65 |
| 2026-01-27 | IONS | 82.15 | -189.3 | -217.0 | -1.65 |
| 2026-01-28 | IONS | 81.92 | -189.3 | -210.1 | -1.65 |
| 2026-01-29 | IONS | 83.88 | -189.3 | -220.9 | -1.65 |
| 2026-01-30 | IONS | 82.64 | -189.3 | -205.1 | -1.65 |
| 2026-02-02 | IONS | 83.07 | -189.3 | -213.2 | -1.65 |
| 2026-02-03 | IONS | 84.61 | -189.3 | -218.8 | -1.65 |
| 2026-02-04 | IONS | 84.99 | -189.3 | -213.1 | -1.65 |
| 2026-02-05 | IONS | 83.47 | -189.3 | -203.9 | -1.65 |
| 2026-02-06 | IONS | 86.52 | -189.3 | -226.0 | -1.65 |
| 2026-02-09 | IONS | 84.77 | -189.3 | -203.0 | -1.65 |
| 2026-02-10 | IONS | 84.29 | -187.3 | -208.7 | -1.65 |
| 2026-02-11 | IONS | 84.32 | -187.3 | -211.3 | -1.65 |
| 2026-02-12 | IONS | 81.77 | -187.3 | -198.7 | -1.65 |
| 2026-02-13 | IONS | 80.69 | -187.3 | -205.7 | -1.65 |
| 2026-02-17 | IONS | 81.36 | -187.3 | -215.0 | -1.65 |
| 2026-02-18 | IONS | 82.21 | -187.3 | -215.5 | -1.65 |
| 2026-02-19 | IONS | 83.16 | -187.3 | - | -1.65 |
| 2026-02-20 | IONS | 83.17 | -187.3 | - | -1.65 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | IONS | -31.06 | -2.18 | 9.37 |
| 2026-01-26 | IONS | -31.12 | -2.44 | 9.38 |
| 2026-01-27 | IONS | -30.06 | -2.44 | 9.38 |
| 2026-01-28 | IONS | -30.06 | -2.44 | 8.65 |
| 2026-01-29 | IONS | -30.06 | -2.44 | 8.65 |
| 2026-01-30 | IONS | -30.06 | -2.44 | 8.65 |
| 2026-02-02 | IONS | -30.02 | -2.43 | 8.65 |
| 2026-02-03 | IONS | -31.55 | -2.43 | 8.65 |
| 2026-02-04 | IONS | -32.73 | -2.43 | 8.65 |
| 2026-02-05 | IONS | -32.73 | -2.43 | 8.65 |
| 2026-02-06 | IONS | -32.60 | -2.43 | 8.65 |
| 2026-02-09 | IONS | -32.39 | -2.92 | 8.66 |
| 2026-02-10 | IONS | -32.37 | -2.92 | 8.66 |
| 2026-02-11 | IONS | -32.37 | -2.92 | 9.80 |
| 2026-02-12 | IONS | -32.37 | -2.92 | 9.80 |
| 2026-02-13 | IONS | -32.37 | -2.92 | 9.80 |
| 2026-02-17 | IONS | -32.65 | 3.35 | 9.80 |
| 2026-02-18 | IONS | -32.75 | 3.35 | 9.80 |
| 2026-02-19 | IONS | -32.75 | 3.35 | 9.80 |
| 2026-02-20 | IONS | -32.75 | 3.35 | 9.80 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPSā
-0.8
Avg. EPS Est. Current Quarter
-1.19
Avg. EPS Est. Next Quarter
-0.59
Insider Transactions
-32.75
Institutional Transactions
3.35
Beta
0.31
Average Sales Estimate Current Quarter
153
Average Sales Estimate Next Quarter
192
Fair Value
Quality Score
43
Growth Score
39
Sentiment Score
84
Actual DrawDown %
4.1
Max Drawdown 5-Year %
-55.8
Target Price
93.58
P/E
Forward P/E
PEG
P/S
13.92
P/B
21.68
P/Free Cash Flow
EPS
-1.71
Average EPS Est. Cur. Yā
-1.65
EPS Next Y. (Est.)
-2.28
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-26.46
Relative Volume
1.34
Return on Equity vs Sector %
-70.5
Return on Equity vs Industry %
-53
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
Ionis Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1069
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
stock quote shares IONSĀ – Ionis Pharmaceuticals, Inc. Stock Price stock today
news today IONSĀ – Ionis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IONSĀ – Ionis Pharmaceuticals, Inc. yahoo finance google finance
stock history IONSĀ – Ionis Pharmaceuticals, Inc. invest stock market
stock prices IONS premarket after hours
ticker IONS fair value insiders trading